Table 1

Major outcome with the various biologics in severe-critical acute respiratory syndrome coronavirus 2 pneumonia in the San Raffaele studies

Authors
biologics
N of SOC treated patientsDeath rate (%)N of biologic treated patientsDeath rate (%)P value
Della Torre et al 1 Sarilumab 2818287NS
Campochiaro et al 2
Tocilizumab
33333216NS
Cavalli et al 8
Anakinra
164429 (high dose)100.009
De Luca et al 9
Mavrilimumab
2627130Fisher’s exact t
=0.08